Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? [electronic resource]
Producer: 20120919Description: 474-83 p. digitalISSN:- 2047-4881
- Atorvastatin
- Bayes Theorem
- Cardiovascular Diseases -- drug therapy
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Drug Costs
- Drug Prescriptions -- economics
- Drugs, Generic -- administration & dosage
- Fluorobenzenes -- administration & dosage
- Heptanoic Acids -- administration & dosage
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- administration & dosage
- Markov Chains
- Medication Adherence
- Models, Economic
- Pyrimidines -- administration & dosage
- Pyrroles -- administration & dosage
- Quality Indicators, Health Care -- economics
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Rosuvastatin Calcium
- Secondary Prevention -- economics
- Simvastatin -- administration & dosage
- Sulfonamides -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.